Entrada Therapeutics Q2 net loss narrows on lower costs

Entrada Therapeutics

05/08/2026 12:23

Overview
Biopharmaceutical firm's Q2 net loss narrowed
Q2 collaboration revenue fell year-over-year

Outlook
Company believes cash position will fund operations into Q3 2027

Result Drivers
COLLABORATION REVENUE DECLINE - Co said Q2 collaboration revenue fell mainly due to lower contributions from partnerships
LOWER R&D COSTS - Co attributed decreased R&D expenses to lower personnel and facility costs, partially offset by higher DMD program expenses
REDUCED G&A EXPENSES - Co said lower professional services costs drove decrease in G&A expenses

Company press release: ID:nGNX2h0KKY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$42.76 mln
 
Q2 Income From Operations
 
-$44.96 mln
 
Q2 Operating Expenses
 
$45.86 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Entrada Therapeutics, Inc. is $20.00, about 176.2% above its August 4 closing price of $7.24

Reuters Recommended Reads
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income
Aug 3 - Keros Therapeutics Q2 net loss narrows on lower expenses
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)